As part of the FDA's rolling review of the biologics license application, Vertex expects to submit the first module to the regulator for potential accelerated approval before the end of 2025, and said ...

This article was reviewed by Knox Beasley, MD Oral vs. Topical Minoxidil: Which Is Better for Hair Loss? Minoxidil is one of ...

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

CSIR NET Application Form 2025 Out: The National Testing Agency (NTA) has issued the official notification for the CSIR UGC NET December 2025 Exam. Candidates aspiring for Junior Research Fellowship ...

With the business potentially at an important milestone, we thought we'd take a closer look at Vertex, Inc.'s (NASDAQ:VERX) future prospects. Vertex, Inc., together with its subsidiaries, provides ...

A real braindump is when someone takes the official exam, memorizes as many questions as possible, and publishes them online.

SSC CPO Apply Online 2025: The Staff Selection Commission has released the SSC CPO Notification 2025 PDF, announcing 3073 vacancies for Sub-Inspector posts. Candidates who have passed graduation can ...

First, pick your designation of choice. In this case, it’s Google’s Professional Machine Learning Engineer certification. Then look up the exam objectives and make sure they match your career goals ...

Kapiva, a healthcare brand focused on Ayurveda-based products, has raised $60 million in a Series D funding round. The round included $28 million in primary capital and was led by 360 ONE Asset and ...

Saudi Arabia now offers Indian travellers multiple visa options, including e-visas and visa-on-arrival under specific conditions. With mandatory travel insurance and clearly defined eligibility, the ...

Kapiva is currently operating at an annual revenue run rate (ARR) of Rs 550 crore, up from Rs 350 crore in FY25, reflecting strong consumer adoption across categories and channels Bengaluru-based ...

Vertex gets EU okay to treat younger cystic fibrosis patients A new EMA approval has expanded the use of Vertex Pharma’s cystic fibrosis therapy Symkevi to children as young as six if they have ...